Patent ductus arteriosus is a heart condition affecting newborns, particularly those born prematurely, where a blood vessel that should close after birth remains open, potentially affecting blood flow between the heart and lungs. The management of this condition varies widely depending on the size of the opening and the baby’s age, with treatment options ranging from careful observation to medication, catheter procedures, or surgery.

How Doctors Approach Patent Ductus Arteriosus Care

When a baby is born with patent ductus arteriosus, the main focus of treatment is to prevent complications while supporting the baby’s growth and development. The approach depends heavily on whether the opening causes symptoms and how much extra blood flows to the lungs. Small openings might not require any intervention at all, especially since many close on their own during the first year of life. Larger openings, however, can force the heart and lungs to work much harder than they should, potentially leading to breathing difficulties, feeding problems, and poor weight gain.^[1]

Medical professionals recognize that patent ductus arteriosus affects babies differently based on their gestational age at birth. Premature infants face much higher rates of this condition, with up to 90% of babies born before 24 weeks having a persistent opening. The younger the baby at birth, the less likely the vessel will close naturally. This is because the mechanisms that normally trigger closure—increased oxygen levels and decreased prostaglandin levels (hormone-like substances)—are not as developed in premature babies.^[6][10]

The treatment strategy considers multiple factors beyond just the size of the opening. Healthcare providers evaluate whether the baby shows symptoms, how much strain is placed on the heart, whether there is evidence of fluid buildup in the lungs, and how the baby is growing and feeding. For some babies, especially those born at term with small openings, regular monitoring through health checkups may be all that is needed. In contrast, babies with moderate to large openings who develop breathing difficulties or heart failure symptoms require more active intervention.^[8]

Treatment decisions also take into account the risk of complications if the opening remains untreated. Over time, an open ductus arteriosus can lead to several serious problems. Extra blood flowing continuously to the lungs increases pressure in the lung arteries, potentially causing pulmonary hypertension (high blood pressure in the lungs). The heart muscle may weaken from working too hard, leading to heart failure. There is also an increased risk of developing a heart infection called bacterial endocarditis, where bacteria settle on heart tissues. For these reasons, even symptom-free individuals discovered to have patent ductus arteriosus in childhood or adulthood typically receive closure treatment.^[4][12]

Standard Medical Treatment Options

The first line of treatment for babies with patent ductus arteriosus often involves supporting measures before considering medications or procedures. Doctors frequently recommend managing fluid intake and nutrition carefully. Babies who are struggling to feed due to breathing difficulties may receive high-calorie formulas to ensure adequate nutrition despite consuming smaller volumes. Fluid restriction, typically not exceeding 130 milliliters per kilogram per day after the first few days of life, helps prevent excess fluid from accumulating in the lungs. This conservative approach alone has shown good success rates in helping the ductus close naturally in some babies.^[12]

When babies develop symptoms of heart failure due to the patent ductus arteriosus, additional supportive care becomes necessary. Diuretics are medications that help the body eliminate excess fluid through urination, reducing the workload on the heart and clearing fluid from the lungs. This can improve breathing and feeding ability. Adjustments to ventilator settings may also help premature babies who require breathing support, with strategies such as lowering inspiratory time and increasing positive end expiratory pressure to optimize lung function.^[12]

For pharmacologic closure of the ductus arteriosus, two main medications are used: indomethacin and ibuprofen lysine. Both are nonsteroidal anti-inflammatory drugs that work by blocking enzymes called cyclooxygenase (COX), which are responsible for producing prostaglandins. Since prostaglandins are what keep the ductus arteriosus open during fetal life, blocking their production encourages the vessel to close.^[6]

Indomethacin has been used for decades and was the first medication proven effective for closing patent ductus arteriosus. It is typically given intravenously in a series of doses over several days. The medication is most effective when administered within the first 10 to 14 days of life. While indomethacin has shown good success rates in closing the ductus, it can affect blood flow to various organs, particularly the kidneys and intestines, which sometimes limits its use in certain babies.^[6][12]

Ibuprofen lysine represents a newer option for medical closure of patent ductus arteriosus. Clinical studies have demonstrated that ibuprofen lysine shows similar effectiveness to indomethacin in closing the ductus arteriosus but with an improved safety profile, particularly regarding kidney function. This medication causes fewer disturbances to blood flow to the kidneys, making it a preferred choice for many healthcare providers. Like indomethacin, ibuprofen lysine is given intravenously in a course of doses over several days.^[6]

The side effects of these medications require careful monitoring. Both indomethacin and ibuprofen can temporarily affect kidney function, reduce urine output, and in some cases affect platelet function, which is important for blood clotting. They may also impact the intestines, and there is concern about increasing the risk of necrotizing enterocolitis (a serious intestinal condition in premature babies). Healthcare providers carefully assess each baby’s overall condition before deciding whether medication is appropriate.^[6]

When medication fails to close the ductus arteriosus or when the baby’s condition is too severe to wait for medication to work, procedural or surgical closure becomes necessary. The choice between catheter-based closure and surgical ligation depends on several factors including the baby’s size, age, overall health status, and the size and shape of the ductus arteriosus.^[8]

Catheter-Based Closure Procedures

Catheter-based closure has become the preferred method for treating patent ductus arteriosus in older infants, children, and adults. This minimally invasive approach has largely replaced open-heart surgery for many patients. The procedure involves making a small incision, typically in the groin area, and inserting a thin, flexible tube called a catheter into a blood vessel. The cardiologist guides the catheter through the blood vessels until it reaches the heart and the ductus arteriosus. Using imaging systems to visualize the exact position, the doctor then deploys a device designed to seal the opening.^[13][18]

Several types of closure devices are available, each designed to accommodate different sizes and shapes of patent ductus arteriosus. The Amplatzer Duct Occluder is one commonly used device made from braided nitinol wires. Nitinol is a special metal with shape memory characteristics, meaning the device can be compressed to fit through the catheter but will return to its original shape once deployed. The device is specifically shaped to stop blood flow through the opening. Different versions exist, including the Amplatzer Duct Occluder II and the Amplatzer Piccolo Occluder, each with design features suited to particular types of ductus arteriosus.^[13]

Another option for catheter closure involves using coils, particularly for smaller patent ductus arteriosus openings. Coils are small wire devices that are positioned in the ductus arteriosus and promote blood clot formation within the opening, eventually leading to complete closure. Coils may be the device of choice for adults with small patent ductus arteriosus discovered incidentally who need closure primarily to prevent the risk of bacterial endocarditis.^[18]

The catheter-based procedure typically takes one to two hours and is performed in a specialized heart catheterization laboratory. Patients usually receive anesthesia and should not feel significant discomfort during the procedure. One major advantage of this approach is the minimally invasive nature—there is no need for opening the chest, which means faster recovery, shorter hospital stays, and less post-procedure discomfort compared to surgery. Many patients can go home the next day or even the same day in some cases.^[13]

Not every patient is a candidate for catheter-based closure. Very small babies who weigh less than 6 kilograms, or those younger than 6 months of age, may not be suitable candidates depending on the specific device being considered. Certain types of patent ductus arteriosus shapes, particularly very large or window-type openings, may be better suited for surgical closure. Patients with blood clots in their heart or vessels, active infections, or those who cannot tolerate blood-thinning medications may also not be appropriate candidates for device closure.^[13]

Surgical Treatment Approach

Surgical closure of patent ductus arteriosus involves a procedure where the surgeon accesses the ductus arteriosus through an incision in the chest. This operation, called thoracotomy, has been performed successfully for many decades—in fact, the first successful surgical closure of a patent ductus arteriosus was performed in 1938 and marked a landmark achievement in congenital heart surgery. During the surgery, the surgeon identifies the ductus arteriosus and either ties it closed with sutures (surgical ligation) or divides and closes it.^[7][12]

Surgery remains an important option for several groups of patients. Premature babies who are critically ill and too small or unstable for catheter procedures often require surgical ligation. Babies whose ductus arteriosus is resistant to medication (some very premature babies do not respond to indomethacin or ibuprofen) may need surgical closure. Patients with very large or unusually shaped openings that cannot accommodate closure devices also benefit from surgery. Additionally, if a catheter-based closure attempt is unsuccessful or not feasible for anatomical reasons, surgery provides a reliable alternative.^[8][12]

The surgical approach carries its own set of risks that must be weighed against the benefits. During the operation, structures near the ductus arteriosus can potentially be injured. The recurrent laryngeal nerve, which controls vocal cord movement, runs close to the ductus arteriosus and is the most commonly injured structure during ligation. Damage to this nerve can affect voice and swallowing. Other structures at risk include the phrenic nerve, which controls diaphragm movement and therefore breathing, and the thoracic duct, which is part of the lymphatic system. However, these complications are relatively uncommon when surgery is performed by experienced pediatric cardiovascular surgeons.^[7]

Post-surgical recovery typically requires several days in the hospital. Babies need pain management and close monitoring for any complications. The surgical incision needs to heal, and healthcare providers watch for signs of infection or other surgical complications. While recovery takes longer than with catheter-based closure, surgical ligation is highly effective with success rates exceeding 95% in closing the patent ductus arteriosus permanently.^[8]

Treatment in Clinical Trials

Based on the source materials provided, there is no specific information available about experimental treatments or clinical trials testing novel drugs or therapies for patent ductus arteriosus. The sources focus primarily on established treatment approaches including the two FDA-approved medications (indomethacin and ibuprofen lysine), catheter-based closure devices, and surgical ligation.

Current research efforts appear to be focused on optimizing the use of existing treatments rather than developing entirely new therapeutic approaches. Studies continue to evaluate the best timing for intervention, comparing early versus conservative management strategies, and assessing which babies are most likely to benefit from specific treatments. Research also examines ways to predict which patent ductus arteriosus cases will close spontaneously and which require intervention, potentially helping avoid unnecessary treatments.^[10]

Most common treatment methods

• Conservative Management
  • Regular health checkups and monitoring for small patent ductus arteriosus that may close on their own
  • Fluid restriction to prevent excess fluid accumulation in the lungs, typically not exceeding 130 mL/kg per day beyond day 3 of life
  • High-calorie formula or breast milk to support adequate nutrition and growth
  • Diuretic medications to help eliminate excess fluid and reduce workload on the heart
  • Ventilation adjustments including lowering inspiratory time and increasing positive end expiratory pressure
• Pharmacologic Closure
  • Indomethacin given intravenously to block prostaglandin production and encourage ductus closure, most effective in the first 10-14 days of life
  • Ibuprofen lysine administered intravenously as an alternative to indomethacin with similar efficacy but improved safety profile, particularly regarding kidney function
  • Both medications work by inhibiting cyclooxygenase enzymes that produce prostaglandins, the hormones that keep the ductus open
• Catheter-Based Closure
  • Minimally invasive procedure using devices such as the Amplatzer Duct Occluder, Amplatzer Duct Occluder II, or Amplatzer Piccolo Occluder
  • Coil closure for smaller patent ductus arteriosus openings
  • Procedure performed through a small groin incision with catheter guidance to the heart
  • Devices made from nitinol wire that maintain their shape and permanently seal the opening
  • Typically requires 1-2 hours in a catheterization laboratory with faster recovery than surgery
• Surgical Closure
  • Thoracotomy with surgical ligation or division of the ductus arteriosus
  • Used for premature infants too small for catheter procedures
  • Appropriate for very large or unusually shaped openings not suitable for device closure
  • Option when medication fails or catheter procedure is unsuccessful
  • Highly effective with success rates exceeding 95% for permanent closure

Long-Term Outlook and Follow-Up

The prognosis for babies and children with patent ductus arteriosus is generally excellent when the condition is identified and treated appropriately. Small patent ductus arteriosus openings that close spontaneously or with medication typically result in completely normal heart function with no long-term complications. Children who undergo successful catheter-based closure or surgical ligation can expect normal growth, development, and physical activity levels.^[8]

After treatment, patients require follow-up care to ensure the closure remains complete and no complications develop. For catheter-based closures, follow-up typically includes echocardiography at specific intervals to confirm the device is properly positioned and the opening is fully sealed. Small residual leaks occasionally persist immediately after device placement but usually close completely within several months as tissue grows over the device.^[18]

Patients who had patent ductus arteriosus closure should inform healthcare providers about their history, particularly dentists and other practitioners who perform procedures that might introduce bacteria into the bloodstream. While the risk of endocarditis decreases significantly after successful closure, some guidelines recommend antibiotic prophylaxis during certain procedures for a period after device placement, until the device becomes fully covered with tissue (typically 6 months).^[12]

Adults who had patent ductus arteriosus that went undetected until adulthood but underwent successful closure can also expect good outcomes, though they require ongoing cardiac follow-up. If the patent ductus arteriosus caused long-standing increased pressure in the lung arteries, this may not fully reverse after closure, and monitoring for pulmonary hypertension remains important.^[18]